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Introduction
Urothelial carcinoma of the bladder in young patients
is rare, and less than 1% of such tumors present in the
first 4 decades of life.1,2 Although the biologic behavior
and treatment of bladder cancer has been well studied,
conflicting reports exist about clinical behavior and
prognosis for patients under 40 years of age. Whether
younger patients have a better prognosis than their
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older counterparts has long been a subject of debate;
indeed, some groups observed similar patterns of clinical
behavior and prognosis for bladder cancer in young and
older patients,1–4 whereas other investigators reported
lower rates of disease recurrence and progression, and
better survival, in younger patients.5–8 In our study, we
evaluated presenting symptoms, disease recurrence
and survival in patients 40 years old or younger with
urothelial carcinoma of the urinary bladder.
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Methods
Study population and protocol
We retrospectively reviewed the charts of 30 consecutive
patients, aged 40 years or younger, with bladder
cancer treated at our institution between May 1990
and October 2003. Demographic data, initial
transurethral resection pathology, recurrence and
progression events, intravesical instillation therapy,
radical cystectomy data, local and distant recurrence,
adjuvant therapies, and disease status, were recorded.
The pathologic stage of bladder cancer was assessed
according to the tumor-node-metastasis (TNM) clas-
sification.9 Tumor grade was assessed according to the
grading system established by the World Health
Organization:10 grades I and II were categorized as
low grade; and grade III as high grade. Patients with
non-transitional cell histology, and those with a history
of upper urinary tract involvement, were excluded
from the study. Disease progression was defined as the
conversion, by pathologic stage, of superficial to invasive
bladder cancer. Death from bladder cancer, or evidence
of local or distant disease recurrence, was classified as
treatment failure, and patients who survived without
evidence of disease, or who were lost to follow-up,
were censored. Survival was defined as the time from
initial presentation to the study end point, including
death or censoring.
Statistical analyses
Patients were stratified into 2 subgroups according to
tumor stage (superficial and invasive). Superficial
bladder cancer includes pTa and pT1 tumors. Invasive
bladder cancer includes pT2, pT3 and pT4 tumors.
For survival analysis, we used 3 end points: disease-
specific survival; disease-free recurrence in superficial
and invasive bladder cancer; and disease-free pro-
gression. The Chi-squared test was used to analyze
correlations in the 2 subgroups. Survival curves were
plotted using the Kaplan-Meier method, with statistical
significance calculated according to the log-rank test.
Data were analyzed using SPSS version 11.0 (SPSS
Inc, Chicago, IL, USA). A p value of less than 0.05 was
considered statistically significant.
Results
The mean age of the patients at initial diagnosis was
34.3 ( 5 years (range, 22–40 years), and the male:
female ratio was 3.3:1 (23 males, 7 females). The mean
follow-up period was 72.8 months (range, 4–149
months). The most common presenting symptoms
were hematuria in 28 patients (93.3%), dysuria in 3
(10%), and flank pain in 2 (6.7%).
Of the 30 patients, 24 (80%) initially had superficial
bladder cancer and 6 had invasive bladder cancer.
Initial cancer staging was as follows: pTa (n = 15), pT1
(9), pT2 (4), pT3 (1), and pT4 (1). There were 26
low-grade and 4 high-grade cases (Table 1). All 24
patients with superficial bladder cancer underwent
transurethral resection of bladder tumor. Twenty-two
patients (73%) had postoperative intravesical instillation
therapy, with mitomycin (n = 10), adriamycin (6),
epirubicin (3), or thiotepa (1). Six patients with invasive
bladder cancer underwent radical cystectomy. Four
patients had urinary diversion with a neobladder, 1
with an ileal conduit, and 1 with a Kock pouch. Five
patients (83%) with invasive bladder cancer had adjuvant
cisplatin-based chemotherapy.
Young adults with urothelial carcinoma of the urinary
bladder were divided into 2 age groups. As shown in
Table 1, 6 of the 30 patients (20%) were diagnosed at
or before age 30 years, and 24 (80%) at age 31–40 years.
Among patients aged ) 30 years, 5 had stage Ta–T1
disease, and 1 had stage T2b disease. Among patients
aged 31–40 years, 19 had stage Ta–T1 disease, and 5
had stage T2–T4 disease. The recurrence rates for
superficial bladder cancer in the 2 age groups were 40%
() 30 years) and 52.7% (31–40 years) (Table 1). Thus,
although no statistically significant differences were
identified between the 2 age groups, disease recurrence,
especially of superficial bladder cancer, tended to be
more common in older than younger patients.
During follow-up, 12 patients (50%) with superficial
bladder cancer had a postoperative recurrence within
10.7 months (range, 3–68 months). One patient
(16.7%) with invasive bladder cancer had a recurrence
within 6 months of operation. The proportion of
patients without a recurrence of invasive bladder cancer
was 84.4% (Figure 1). One patient died from invasive
bladder cancer after cystectomy, and another died
from superficial bladder cancer due to tumor
progression. The 5-year cancer-specific survival rate
was 95.2% for superficial bladder cancer and 83% for
invasive bladder cancer. The overall 5-year cancer-
specific survival rate was 93.3% (Figure 2).
Discussion
Urothelial carcinoma of the urinary bladder is the
most common neoplasm of the urinary tract. The peak
incidence occurs in the sixth decade, but the condition
is rarely noted in individuals younger than 40 years
old, thus giving a reported incidence of about 0.8%.1–4
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Figure 2. Overall survival rate of young adults with urothelial
carcinoma of the urinary bladder (95% confidence interval,
128–160 months).
Figure 1. Proportion of patients without a recurrence of superficial
(95% confidence interval, CI, 42–99 months) or invasive bladder
cancer (95% CI, 96–173 months).
Table 1. Characteristics of patients treated for bladder cancer
Age (yr)
Total p*
) 30 31–40
Patients, n (%) 6 (20) 24 (80) 30 (100)
Mean age (range), yr 25.2 36.6 34.3 (22–40)
Males/females 3/3 20/4 23/7 0.65
Mean follow-up (range), mo 86.7 69.3 72.8 (4–149)
Stage at presentation, n (%) 1.00
Ta 3 12 15 (50)
T1 2 7 9 (30)
T2 1 3 4 (13.4)
T3 1 1 (3.3)
T4 1 1 (3.3)
Type at presentation, n (%)
Superficial bladder cancer (Ta, T1) 5 19 24 (80)
Invasive bladder cancer (T2–T4) 1 5 6 (20)
Grade at presentation, n (%) 0.61
Low 5 21 26 (86.7)
High 1 3 4 (13.3)
Intravesical therapy of superficial cancer, n (%) 5/5 17/19 22/24 (91.7) 1.00
Cystectomy, n (%) 1 5 6 (100)
Adjuvant chemotherapy for invasive cancer, n (%) 0 5 5/6 (83.3)
Tumor recurrence, n (%)
Total 2/6 (33.3) 11/24 (45.8) 13/30 (43.3)
Superficial bladder cancer 2/5 (40) 10/19 (52.7) 12/24 (50.0) > 0.05
Invasive bladder cancer 0/1 (0) 1/5 (20) 1/6 (16.7) > 0.05
Tumor progression to invasive cancer, n (%) 0 2 2/24 (8.3)
Mortality, n (%) 2/30 (6.6) > 0.05
Superficial bladder cancer 0/5 (0) 1/19 (5.3) 1/24 (4.2)
Invasive bladder cancer 0/1 (0) 1/5 (20) 1/6 (16.7)
*For 1 age group versus the other.
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Our study, with a male:female ratio of 3.3:1,
demonstrates the usual male predominance of urothelial
bladder carcinoma; this ratio is similar to those in the
reports of Ozbey et al11 and Kurz et al.4 The most
common presenting symptom in the young adults in
our study was gross hematuria, the causes of which
included infection, urolithiasis, and malignancy. The
findings of gross hematuria, the main symptom of
bladder cancer, and irritative bladder symptoms should
be thoroughly investigated to permit the accurate,
differential diagnosis of bladder cancer, especially in
the young group. In our study, there was no significant
difference between patients with superficial or invasive
bladder cancer regarding the occurrence of gross
hematuria.
In our series, 24 young patients (80%) were
initially diagnosed with superficial bladder cancer,
and the remaining 6 (20%) with invasive bladder
cancer. Twelve patients with superficial bladder cancer
had a tumor recurrence within a mean of 10.7 months.
Only 2 of the 24 patients with superficial bladder
cancer (8.3%) progressed to invasive bladder cancer.
Our results are supported by the report of
Yossepowitch and Dalbagni,12 who documented a
progression rate of 16%.
Benson et al5 and Madgar et al6 reported that
tumor recurrences were age-related and tended to
occur more frequently in older than younger patients.
Among 6 patients aged ) 30 years in our study, 5
presented with stage Ta–T1 disease, and 1 with stage
T2b disease; 24 patients aged 31–40 years had stage
Ta–T1 disease (n = 19), or stage T2–T4 disease (5).
Disease recurrence rates in the 2 age groups were
33.3% () 30 years) and 45.8% (31–40 years). Although
this difference was not statistically significant, tumor
recurrence does seem to be age-related.
The prognosis for patients with invasive bladder
cancer is very poor. According to Yossepowitch and
Dalbagni,12 the 5-year rate of disease-free survival after
cystectomy was only 59% in 17 patients. In our series,
the corresponding rate after cystectomy in 6 patients
with invasive bladder cancer was 83%. This discrepancy
may be because more patients with advanced disease
were evaluated in the first report: 8 patients had stage
T3–4 disease,12 whereas only 2 patients did in our
study. Further investigations are now required to
confirm long-term outcomes in young adults with
urothelial bladder cancer.
In conclusion, patients younger than 40 years
old with bladder cancer usually have low-grade and
low-stage tumors. Among this age group, the survival
rate in patients with invasive bladder cancer appears
to be no worse than that in patients with superficial
bladder cancer.
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